nach oben

Current Sexual Health Reports

Erschienen in:

06.10.2022 | Male and Female Surgical Interventions (A Baumgarten, Section Editor)

Review of Sexual Health-Friendly BPH Therapies

verfasst von: Nicholas Zulia, Jonathan Beilan

Erschienen in: Current Sexual Health Reports | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review serves to explore minimally invasive BPH therapies, with a focus on the sexual side effects of each given modality. The article seeks to give the reader a better understanding of the risk of erectile and ejaculatory dysfunction following various bladder outlet procedures and surgeries.

Recent Findings

Multiple urologic treatment technologies are entering the market and gaining FDA approval. UroLift®, Rezūm™, and Aquablation are now supported by the American Urological Association guidelines for the treatment of BPH-related LUTS. Each modality has a relatively low risk of erectile or ejaculatory dysfunction when compared to traditional transurethral resection of the prostate (TURP). Other treatment options, such as prostatic arterial embolization and the Temporarily Implanted Nitinol Device (iTind), may edge their way toward standard of care as new evidence regarding safety and efficacy becomes available.

Summary

Various treatment modalities have been proven to be safe when considering a bladder outlet procedure. Depending on the patient’s prostatic size, anatomy, and his goals of care, clinicians should be able to offer a BPH treatment option with a favorable prognosis as well as an acceptable risk profile.

Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I-initial work-up and medical management. J Urol. 2021;206(4):806–17. https://doi.org/10.1097/JU.0000000000002183.CrossRefPubMed

Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9. https://doi.org/10.1016/s0022-5347(17)49698-4.CrossRefPubMed

Suarez-Ibarrola R, Miernik A, Gratzke C, Schoeb DS. Reasons for new MIS. Let’s be fair: iTIND, Urolift and Rezum. World J Urol. 2021;39(7):2315–27. https://doi.org/10.1007/s00345-020-03453-z.

Das AK, Han TM, Uhr A, Roehrborn CG. Benign prostatic hyperplasia: an update on minimally invasive therapy including Aquablation. Can J Urol. 2020;27(S3):2–10.PubMed

Leong JY, Patel AS, Ramasamy R. Minimizing sexual dysfunction in BPH surgery. Curr Sex Health Rep. 2019;11(3):190–200. https://doi.org/10.1007/s11930-019-00210-1.CrossRefPubMedPubMedCentral

Press release: Teleflex announces FDA clearance for expanded indication of the UroLift® system for treatment of larger prostates, up to 100cc. 2020. https://www.urolift.com/press-releases/fda-expanded-indication-up-to-100cc. Accessed June 25 2022.

Rukstalis D, Grier D, Stroup SP, Tutrone R, deSouza E, Freedman S, et al. Prostatic urethral lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. Prostate Cancer Prostatic Dis. 2019;22(3):411–9. https://doi.org/10.1038/s41391-018-0118-x.CrossRefPubMed

Annese P, d’Altilia N, Mancini V, Falagario UG, Del Giudice F, Ferro M, et al. Preserving ejaculatory function in young patients with lower urinary tract symptoms: medium- to long-term follow-up of prostatic urethral lift at a single center. Ther Adv Urol. 2021;13:17562872211037108. https://doi.org/10.1177/17562872211037109.CrossRefPubMedPubMedCentral

Sievert KD, Schonthaler M, Berges R, Toomey P, Drager D, Herlemann A, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. World J Urol. 2019;37(7):1353–60. https://doi.org/10.1007/s00345-018-2494-1.CrossRefPubMed

10.

Beilan J WJ, Emtage J, Moscowitz A, Ortega-Vilches A, Bickell M, Parker J, Hernandez DJ, Carrion RE, Perito P, editor. Prostatic urethral lift offers relief in patients planning for penile prosthesis. WAMS 4th Congress for Medical Sexology; 2015 Oct 10, 2015; Miami, FL.

11.

Baboudjian M, Fourmarier M, Gondran-Tellier B, Pradere B, Userovici M, Alegorides C, et al. Head-to-head comparison of prostatic urethral lift and water vapor thermal therapy for the treatment of symptomatic benign prostatic hyperplasia: a real-life study. Int Urol Nephrol. 2021;53(9):1757–63. https://doi.org/10.1007/s11255-021-02899-3.CrossRefPubMed

12.

Magistro G, Chapple CR, Elhilali M, Gilling P, McVary KT, Roehrborn CG, et al. Emerging minimally invasive treatment options for male lower urinary tract symptoms. Eur Urol. 2017;72(6):986–97. https://doi.org/10.1016/j.eururo.2017.07.005.CrossRefPubMed

13.

Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rezum system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology. 2015;86(5):1042–7. https://doi.org/10.1016/j.urology.2015.05.046.CrossRefPubMed

14.

Garden EB, Shukla D, Ravivarapu KT, Kaplan SA, Reddy AK, Small AC, et al. Rezum therapy for patients with large prostates (>/= 80 g): initial clinical experience and postoperative outcomes. World J Urol. 2021;39(8):3041–8. https://doi.org/10.1007/s00345-020-03548-7.CrossRefPubMedPubMedCentral

15.

Siena G, Cindolo L, Ferrari G, Maruzzi D, Fasolis G, Condorelli SV, et al. Water vapor therapy (Rezum) for lower urinary tract symptoms related to benign prostatic hyperplasia: early results from the first Italian multicentric study. World J Urol. 2021;39(10):3875–80. https://doi.org/10.1007/s00345-021-03642-4.CrossRefPubMedPubMedCentral

16.

Ines M, Babar M, Singh S, Iqbal N, Ciatto M. Real-world evidence with the Rezum system: a retrospective study and comparative analysis on the efficacy and safety of 12 month outcomes across a broad range of prostate volumes. Prostate. 2021;81(13):956–70. https://doi.org/10.1002/pros.24191.CrossRefPubMed

17.

McVary KT, Gittelman MC, Goldberg KA, Patel K, Shore ND, Levin RM, et al. Final 5-year outcomes of the multicenter randomized sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206(3):715–24. https://doi.org/10.1097/JU.0000000000001778.CrossRefPubMed

18.

Product instructions: Rezūm™ Delivery Device Kit for BPH Boston Scientific. 2019. https://www.bostonscientific.com/content/dam/bostonscientific/uro-wh/portfolio-group/lithotripsy/rezum/50998296-01a_rezum_dfu_en_s.pdf. Accessed August 18 2022.

19.

Zorn KC, Bidair M, Trainer A, Arther A, Kramolowsky E, Desai M, et al. Aquablation therapy in large prostates (80–150 cc) for lower urinary tract symptoms due to benign prostatic hyperplasia: WATER II 3-year trial results. BJUI Compass. 2022;3(2):130–8. https://doi.org/10.1002/bco2.121.CrossRefPubMed

20.

Bach T, Gilling P, El Hajj A, Anderson P, Barber N. First multi-center all-comers study for the aquablation procedure. J Clin Med. 2020;9(2). https://doi.org/10.3390/jcm9020603.

21.

Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, et al. Aquablation for benign prostatic hyperplasia in large prostates (80–150 cc): 1-year results. Urology. 2019;129:1–7. https://doi.org/10.1016/j.urology.2019.04.029.CrossRefPubMed

22.

Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Three-year outcomes after aquablation therapy compared to TURP: results from a blinded randomized trial. Can J Urol. 2020;27(1):10072–9.PubMed

23.

Yee CH, Tang SF, Yuen SK, Chan CK, Teoh JYC, Chiu PKF, et al. Technique, outcome and changes in prostate dimensions in patients with urinary retention managed by aquablation. Int Urol Nephrol. 2022. https://doi.org/10.1007/s11255-022-03244-y.CrossRefPubMedPubMedCentral

24.

Xu Z, Zhou Z, Mu Y, Cai T, Gao Z, Liu L. An updated meta-analysis of the efficacy and safety of prostatic artery embolization vs. transurethral resection of the prostate in the treatment of benign prostatic hyperplasia. Front Surg. 2021;8:779571. https://doi.org/10.3389/fsurg.2021.779571.

25.

Abt D, Schmid HP, Speakman MJ. Reasons to consider prostatic artery embolization. World J Urol. 2021;39(7):2301–6. https://doi.org/10.1007/s00345-021-03601-z.CrossRefPubMed

26.

Marzano L, Thiounn N, Pereira H, Pellerin O, Dariane C, Del Giudice C, et al. Prostatic artery embolization allows to maintain full sexual activity in patients suffering from bothersome lower urinary tracts symptoms related to benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2020;43(8):1202–7. https://doi.org/10.1007/s00270-020-02520-7.CrossRefPubMed

27.

Mullhaupt G, Hechelhammer L, Diener PA, Engeler DS, Gusewell S, Schmid HP, et al. Ejaculatory disorders after prostatic artery embolization: a reassessment of two prospective clinical trials. World J Urol. 2020;38(10):2595–9. https://doi.org/10.1007/s00345-019-03036-7.CrossRefPubMed

28.

Bilhim T, Costa NV, Torres D, Pisco J, Carmo S, Oliveira AG. Randomized clinical trial of balloon occlusion versus conventional microcatheter prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2019;30(11):1798–806. https://doi.org/10.1016/j.jvir.2019.06.019.CrossRefPubMed

29.

Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, et al. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020;38(12):3235–44. https://doi.org/10.1007/s00345-020-03140-z.CrossRefPubMed

30.

Elterman D, Gao B, Zorn KC, Bhojani N, Chughtai B. How I do it: temporarily implanted nitinol device (iTind). Can J Urol. 2021;28(4):10788–93.PubMed

31.

Amparore D, Fiori C, Valerio M, Schulman C, Giannakis I, De Cillis S, et al. 3-year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2021;24(2):349–57. https://doi.org/10.1038/s41391-020-00281-5.CrossRefPubMed

32.

De Nunzio C, Cantiello F, Fiori C, Crocerossa F, Tognoni P, Amparore D, et al. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. World J Urol. 2021;39(6):2037–42. https://doi.org/10.1007/s00345-020-03418-2.CrossRefPubMed

33.

The ProVerum First in Man PROVE Study. U.S. National Library of Medicine. 2019. https://clinicaltrials.gov/ct2/show/study/NCT03972371. Accessed July 7 2022.

34.

ProVerum: first enrolment in the ProVIDE clinical study for BPH treatment. PR Newswire. 2022. https://www.prnewswire.com/news-releases/proverum-first-enrolment-in-the-provide-clinical-study-for-bph-treatment-301566430.html. Accessed July 7 2022.

Titel: Review of Sexual Health-Friendly BPH Therapies
verfasst von: Nicholas Zulia
Jonathan Beilan
Publikationsdatum: 06.10.2022
Verlag: Springer US
Erschienen in: Current Sexual Health Reports / Ausgabe 4/2022
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-022-00344-9

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Review of Sexual Health-Friendly BPH Therapies

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Long-term Complications of Hypospadias Repair

The Relationship Between Sleep and Sexual Function in Women

Current Considerations in Interventions to Address Sexual Function and Improve Care for Women with Cancer

“Pumpology”: Evolution of the Penile Implant Pump and What Is on the Horizon

Sexual Trauma Moderates Hormonal Mediators of Women’s Sexual Function

Effects of Cannabis Use on Sexual Function in Women: a Review

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Fehlerkultur in der Medizin – Offenheit zählt!

Update Urologie